Absorption Systems Becomes Society of Toxicology Affiliate
News Mar 02, 2010
Absorption Systems has joined the Society of Toxicology, the global professional association of toxicologists, as an SOT Affiliate.
The firm, a contract research organization, has more than a decade of experience assisting pharmaceutical and biotechnology companies in determining which compounds in development should be advanced into clinical testing. Absorption Systems had focused on ADME testing for years, and broadened its portfolio of services to include toxicology through the mid-2009 acquisition of an AAALAC-accredited GLP toxicology testing facility in San Diego, CA.
Absorption Systems pioneered the Caco-2 cell model for in vitro prediction of oral drug absorption. Today, the 100-person company offers a broad service portfolio, including in vitro, in situ and in vivo models to assess the ADMET properties of small molecules.
Additionally, Absorption Systems provides in vivo testing of the safety and efficacy of both small molecule drugs and biologics, medical devices, cardiovascular and CNS pharmacology, diabetes, psoriasis and neutropenia.
“Absorption Systems is proud to become an affiliate of the Society of Toxicology and will work to contribute to the organization’s continued success,” said Dr. Sarath Kanekal, Absorption Systems’ Vice President of Pharmacology and Toxicology and an SOT member for over 20 years.
“Absorption Systems has long been active in helping drug companies more rapidly advance candidates to clinical testing. Now we have added toxicology to that toolkit. We believe that by joining with others in industry and research, we can make a greater impact in helping our customers better appreciate the importance of conducting high-quality, regulatory-driven toxicology studies.”
More than 60 years after the drug thalidomide caused birth defects in thousands of children whose mothers took the drug while pregnant, scientists have solved a mystery that has lingered ever since the dangers of the drug first became apparent: how did the drug produce such severe fetal harm?READ MORE
Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent painful swellings of the skin and mucous membranes. A new drug has been developed to help prevent attacks of hereditary angioedema. It has now been investigated in an international study performed at over 26 university facilities in Europe, Canada and Australia.READ MORE